Cellular and Molecular Adaptations to Exercise-induced Inflammatory Response in Children With Autoimmune Diseases

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02502539

Acronym

AJI-APA

Enrollment

Registered

2015-07-20

Start date

2015-07-31

Completion date

2017-01-31

Last updated

2016-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Idiopathic Arthritis

Keywords

Juvenile idiopathic arthritis, Physical exercise, Pro-anti-inflammatory balance, Interleukins, miRNA, Calgranulins

Brief summary

Juvenile idiopathic arthritis (JIA) is a chronic disease characterized by persistent joint inflammation. The immune system disruption that leads to overproduction of pro-inflammatory cytokines (TNF-α, IL-1, IL-6) is a cascade of events on different levels-some molecular, some cellular, and some systemic. Our objective is to identify the mechanisms through which physical activity is liable to mediate inflammatory balance in autoimmune disease settings, and specifically in JIA patients.

Detailed description

Feasibility study

Interventions

PROCEDUREControlled physical activity

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

8 Years to 12 Years

Healthy volunteers

Inclusion criteria

* Children between 8 and 12 years * Tanner stage \< T2 * polyarthritis, oligoarthritis and ERA sub-type of JIA * Stable disease during 3 months before starting study

Exclusion criteria

* Infection * Fever * Anti-IL6 treatment * More than 6h per week of physical activity * Systemic corticosteroid treatment during the 3 months before starting study * Systemic JIA * JIA not mastered by treatments * Other autoimmunity or auto-inflammatory diseases * Participation in another clinical research protocol

Design outcomes

Primary

Measure	Time frame	Description
Percent change	AT DAY 1	Percent change, before and after a controlled session of physical activity session, of serum and secretion kinetics of IL-6 and its soluble receptors (sIL- 6R and sgp130)

Secondary

Measure	Time frame	Description
locomotors function (CHAQ)	at day 1	to assess slipping quality
swelling of knee	at day 1	to assess slipping quality
pain (VAS)	at day 1	to assess slipping quality
plasma level of melatonin	at day 1	to assess slipping quality
sitfness of knee	at day 1	to assess slipping quality
rate of miRNA	at day 1	to assess slipping quality

Countries

France

Contacts

Primary ContactPatrick LACARIN

placarin@chu-clermontferrand.fr04 73 75 11 95

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026